Chris Carpenter

Chris Carpenter

Company: Rubius Therapeutics

Job title: CMO


A New Era in Cellular Medicine for Phenylketonuria 10:00 am

• Most phenylketonuria patients rely on a protein-restrictive diet to control their disease that is difficult to adhere to and does not always work • Rubius Therapeutics is developing an investigational enzyme replacement therapy engineered inside a red blood cell called RTX-134 • RTX-134 is designed to overcome many of the challenges with current treatment…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.